Graves’ Disease patients face limited treatment options that do not irreversibly destroy the thyroid (MARKETVUE® REPORT)
Less than half of Graves' Disease patients achieve remission with anti-thyroid drugs, and nearly half of those that do will relapse. NEWTON, Mass., Aug. 16, 2023 /PRNewswire/ - Graves' Disease (GD) is [...]
Ophthalmologists estimate 10% of Geographic Atrophy patients are now treated with Syfovre since its February 2023 approval (MARKETVUE® REPORT)
Apellis's anti-C3 Syfovre (pegcetacoplan intravitreal injection) and Astellas' anti-C5 Izervay (avacincaptad pegol intravitreal injection) were both recently FDA-approved to treat Geographic Atrophy (GA), but physicians are eager for more treatment [...]
Filspari and Tarpeyo launches off to a great start in IgAN (MARKETVUE® REPORT)
Surveyed nephrologists by REACH Market Research report that Filspari and Tarpeyo are already being prescribed to as many as 1 in 5 IgAN patients. NEWTON, Mass., July 27, 2023 /PRNewswire/ -- IgA nephropathy (IgAN) is [...]
~20% of Dupixent-treated atopic dermatitis patients are refractory to the drug (MARKETVUE® REPORT)
While non-response to Dupixent is uncommon, atopic dermatitis (AD) patients who are refractory lack safe and effective treatments. NEWTON, Mass., July 26, 2023 /PRNewswire/ -- Atopic dermatitis (AD) is a chronic, inflammatory [...]
Graves’ Disease patients face limited treatment options that do not irreversibly destroy the thyroid (MARKETVUE® REPORT)
Less than half of Graves' Disease patients achieve remission with anti-thyroid drugs, and nearly half of those that do will relapse. NEWTON, Mass., Aug. 16, 2023 /PRNewswire/ - Graves' Disease (GD) is [...]
Ophthalmologists estimate 10% of Geographic Atrophy patients are now treated with Syfovre since its February 2023 approval (MARKETVUE® REPORT)
Apellis's anti-C3 Syfovre (pegcetacoplan intravitreal injection) and Astellas' anti-C5 Izervay (avacincaptad pegol intravitreal injection) were both recently FDA-approved to treat Geographic Atrophy (GA), but physicians are eager for more treatment [...]
Filspari and Tarpeyo launches off to a great start in IgAN (MARKETVUE® REPORT)
Surveyed nephrologists by REACH Market Research report that Filspari and Tarpeyo are already being prescribed to as many as 1 in 5 IgAN patients. NEWTON, Mass., July 27, 2023 /PRNewswire/ -- IgA nephropathy (IgAN) is [...]
~20% of Dupixent-treated atopic dermatitis patients are refractory to the drug (MARKETVUE® REPORT)
While non-response to Dupixent is uncommon, atopic dermatitis (AD) patients who are refractory lack safe and effective treatments. NEWTON, Mass., July 26, 2023 /PRNewswire/ -- Atopic dermatitis (AD) is a chronic, inflammatory [...]